Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Completed · Phase 1/Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It may also make tumor cells more sensitive to radiation therapy. Giving radiation therapy together with erlotinib may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given together with radiation therapy and to see how well they work in treating young patients with newly diagnosed glioma.
Key facts
- Study ID
- NCT00124657
- Run by
- St. Jude Children's Research Hospital
- People needed
- 62
- Starts
- 2005-03-01
- Expected to finish
- 2014-09-01
- Last updated by the study team
- 2015-12-04
Who can join
Age: 3 and older, up to 21. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California San Diego — San Diego, California, United States
- Duke Children's Hospital and Health Center — Durham, North Carolina, United States
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.